Chronic Schizophrenia (DBCOND0031717)

Identifiers

Synonyms

Chronic schizophrenia / Chronic schizophrenia (disorder) / Schizophrenia, unspecified / Schizophrenia NOS / Dementia praecox / Schizophrenic disorders (disorder) / Unspecified schizophrenia / Unspecified schizophrenia, unspecified state / Schizophrenia / Schizophrenia (disorder)

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Amisulpride	A dopamine D2 receptor antagonist used in the treatment of acute and chronic schizophrenia, and in the prevention and treatment of postoperative nausea and vomiting in adults.	D(2) dopamine receptortarget D(3) dopamine receptortarget 5-hydroxytryptamine receptor 7target 5-hydroxytryptamine receptor 2Atarget Erythrocytecarrier Multidrug and toxin extrusion protein 1transporter Multidrug and toxin extrusion protein 2transporter ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Solute carrier family 22 member 1transporter Mu-type opioid receptortarget Delta-type opioid receptortarget Kappa-type opioid receptortarget
Flupentixol	A thioxanthene neuroleptic used to treat schizophrenia and depression.	Alpha-1A adrenergic receptortarget D(2) dopamine receptortarget D(1A) dopamine receptortarget Aromatic-L-amino-acid decarboxylaseenzyme 5-hydroxytryptamine receptor 2Atarget ATP-dependent translocase ABCB1transporter Muscarinic acetylcholine receptor M1target Liver carboxylesterase 1enzyme D(3) dopamine receptortarget D(4) dopamine receptortarget 5-hydroxytryptamine receptor 2Ctarget
Pipotiazine	An antipsychotic indicated for the management of chronic, non-agitated schizophrenic patients.	Cytochrome P450 2D6enzyme Cytochrome P450 3A4enzyme D(2) dopamine receptortarget D(1A) dopamine receptortarget 5-hydroxytryptamine receptor 2Atarget 5-hydroxytryptamine receptor 1Atarget Solute carrier family 22 member 1transporter Albumincarrier Cytochrome P450 2C19enzyme
Sulpiride	A selective D2 dopamine receptor antagonist indicated to treat chronic and acute schizophrenia.	D(2) dopamine receptortarget D(3) dopamine receptortarget Cholinesteraseenzyme Carbonic anhydrase 2target Carbonic anhydrase 3target Albumincarrier Solute carrier family 22 member 1transporter Solute carrier family 22 member 2transporter Multidrug and toxin extrusion protein 1transporter Multidrug and toxin extrusion protein 2transporter D(4) dopamine receptortarget Solute carrier family 22 member 3transporter ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter
Zuclopenthixol	An antipsychotic indicated for the management of schizophrenia. The acuphase formulation is indicated for initial treatment of acute psychosis or exacerbation of psychosis, while the depot formulation is best for maintenance.	D(1A) dopamine receptortarget D(1B) dopamine receptortarget D(2) dopamine receptortarget Cytochrome P450 2D6enzyme Alpha-1A adrenergic receptortarget Alpha-2A adrenergic receptortarget 5-hydroxytryptamine receptor 2Atarget Histamine H1 receptortarget Cytochrome P450 3A4enzyme

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT06206798	Resourcefulness Group Intervention on Recovery and Quality of Life	No drug interventions	supportive_care	Not Available	completed
NCT02298985	Curcumin Addition to Antipsychotic Treatment in Chronic Schizophrenia Patients	Curcumin	treatment	4	completed
NCT00525863	Oxygen Therapy in Schizophrenia	Oxygen	treatment	3	unknown_status
NCT05809882	Study of Experience of High-frequency Repetitive Transcranial	No drug interventions	treatment	Not Available	completed
NCT02624167	A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia	No drug interventions	treatment	2	completed
NCT02421146	The Effect of Transcranial Direct Current Stimulation on Human Brains: A Neuroimaging Study	No drug interventions	other	Not Available	completed
NCT01450514	POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia	Paliperidone Pipamperone Risperidone	treatment	2	completed
NCT00789698	Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia	Lurasidone Quetiapine	treatment	3	completed
NCT01761383	Role of Nintendo Wii in Improving Negative Symptoms and Quality of Life in Chronic Schizophrenia	No drug interventions	treatment	Not Available	completed
NCT03275909	Integrated Psychological Therapy for Chronic Schizophrenia	No drug interventions	treatment	Not Available	completed
NCT00148616	Memantine for the Treatment of Cognitive Dysfunction and Negative Symptoms in Patients With Chronic Schizophrenia	Memantine Risperidone	treatment	3	terminated
NCT05948696	Experience of Horticultural Group Therapy Among People With Chronic Schizophrenia	No drug interventions	Not Available	Not Available	recruiting
NCT00664274	Relation of Catechol-O-methyltransferase (COMT) Genotype and Response to Cognitive Remediation Schizophrenia	No drug interventions	basic_science	Not Available	unknown_status
NCT01891929	Cognitive Remediation and Sheltered Employment in Schizophrenia	No drug interventions	treatment	Not Available	completed
NCT00161044	An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit Symptoms	Galantamine	treatment	Not Available	completed
NCT06349369	Effect of tDCS on Inflammatory Biomarkers in Chronic Schizophrenia	No drug interventions	treatment	Not Available	recruiting